Welcome to our dedicated page for Evogene SEC filings (Ticker: EVGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Evogene Ltd. (EVGN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. Evogene files reports with the U.S. Securities and Exchange Commission, including Form 20‑F and recurring Form 6‑K reports that furnish financial statements, operating and financial reviews, and information on corporate actions.
For investors analyzing Evogene’s AI‑driven life‑science business, Form 6‑K submissions are particularly important. These filings often include press releases and slide presentations for quarterly results, unaudited condensed consolidated financial statements for interim periods, and operating and financial review and prospects documents. Through these materials, readers can examine revenue contributions from subsidiaries, cost‑reduction measures, restructuring steps, and transactions such as the sale of most of Lavie Bio’s activity and the transfer of the MicroBoost AI for Ag platform to ICL.
Evogene’s filings can also reference shareholder meeting outcomes, proxy materials, and incorporation by reference into registration statements on Form F‑3 and Form S‑8. Together, these documents outline the company’s capital markets activity, equity compensation plans and other corporate matters.
On Stock Titan, EVGN filings are updated as they are furnished to EDGAR, and AI‑powered tools summarize key points from lengthy documents. Users can quickly identify items such as interim financial trends, changes in subsidiary structure, or strategic shifts around tech‑engines like ChemPass AI, MicroBoost AI and GeneRator AI, without reading every page of the original filing.
Evogene Ltd. registers 5,076,924 ordinary shares for resale by a selling shareholder, representing the shares issuable upon exercise of 5,076,924 ordinary warrants issued in an induced warrant exercise transaction completed on February 11, 2026.
The prospectus states the company will receive $6.35 million if the warrants are exercised in full for cash, but will not receive proceeds from secondary sales by the selling shareholder. The filing lists 9,893,764 ordinary shares outstanding as of March 15, 2026 as context, and discloses a 4.99% beneficial ownership limitation applicable to the warrants.
Evogene Ltd. registers resale of 2,446,707 ordinary shares to cover shares issued or issuable upon exercise of previously issued warrants; these shares may be sold by the Selling Shareholder from time to time.
The company will not receive proceeds from resales under this prospectus. Evogene received $3,384,616 in gross cash from the induced warrant exercise. Shares outstanding were 9,893,764 ordinary shares as of March 15, 2026.
Evogene Ltd. files its annual report for the year ended December 31, 2025, highlighting an early‑stage, loss‑making profile with significant risk. The company reported operating losses from continuing operations of approximately $14.0 million in 2025, $18.8 million in 2024 and $22.2 million in 2023 and has a history of negative cash flow.
Management states that conditions raise substantial doubt about Evogene’s ability to continue as a going concern over the 12‑month period from the report date and has prepared a plan focused on liquidity improvements and cost preservation. In 2025 Evogene undertook major streamlining: it sold most of Lavie Bio’s assets to ICL, scaled down Biomica, Casterra and AgPlenus, and implemented a significant reduction in workforce.
The business is now more concentrated around fewer subsidiaries, technological platforms and revenue sources, increasing exposure if remaining programs underperform. Evogene discloses it and its subsidiaries may need substantial additional capital, warns of potential future equity dilution, and notes 5,076,924 outstanding warrants exercisable at $1.25 per share that, if exercised, would dilute existing shareholders.
Evogene Ltd. director Leon Recanati filed a Form 3 reporting his initial ownership in the company. He directly holds 83,886 ordinary shares and multiple stock options over ordinary shares with differing exercise prices and expirations extending through 2035. A footnote explains that the option grant with a 1.29 exercise price vests in four equal quarterly installments from an August 18, 2025 grant date, becoming fully vested after one year.
Evogene Ltd. director Nimrodi Nir filed an initial ownership report showing he holds several stock options to buy Evogene ordinary shares. These options carry exercise prices ranging from $1.29 to $11.00 per share and have expiration dates between 2030 and 2035.
One grant covering 10,000 underlying ordinary shares at an exercise price of $1.29 per share vests in equal quarterly installments of 25%, becoming fully vested on the one-year anniversary of its August 18, 2025 grant date. All reported holdings are listed as directly owned derivative securities rather than common shares.
Evogene Ltd. director Percy Adrian John filed an initial ownership report detailing his stock option holdings in the company. The filing lists several option awards over ordinary shares with exercise prices ranging from 1.2900 to 62.6800 and expirations between 2028 and 2035.
These options cover blocks of 250 to 2,500 underlying ordinary shares each. One grant over 2,500 underlying shares at an exercise price of 1.2900 vests in four equal quarterly installments so that it is fully vested on the one-year anniversary of the August 18, 2025 grant date. The report reflects holdings only, not new market transactions.
Evogene Ltd. Chief Development Officer Gabi Tarcic filed an initial ownership report showing a stock option position. The option gives the right to buy 40,000 ordinary shares at an exercise price of $2.305 per share and expires on November 20, 2034.
According to the vesting terms, 25% of the options vest on the first anniversary of the November 20, 2024 grant date. The remaining options vest in equal quarterly installments of 6.25% over the next twelve quarters, so all options are fully vested four years after the grant date.
Evogene Ltd. filed an initial ownership report for Chief Technology Officer Ilia Zhidkov, detailing his stock option holdings in the company. The filing lists multiple options to buy ordinary shares with exercise prices ranging from 2.3050 to 49.4700 and expiration dates between 2027 and 2034. Footnotes state that certain grants from March 8, 2023 and November 20, 2024 vest 6.25% each quarter over four years until fully vested on their fourth anniversaries.
Evogene Ltd. director Sarit Firon filed an initial Form 3 disclosing stock option holdings in the company. The filing lists multiple stock option grants over ordinary shares with exercise prices ranging from 1.2900 to 70.5500 per share and expiration dates between 2026 and 2035. One grant for options over 2,500 ordinary shares at an exercise price of 1.2900 vests in equal quarterly installments of 25%, becoming fully vested on the one-year anniversary of the August 18, 2025 grant date.
Evogene Ltd. filed a Form 3 detailing the equity holdings of its Chief Financial Officer, Eldad Yaron. He holds 4,100 ordinary shares underlying restricted share units that began vesting on April 1, 2023 at 6.25% per quarter over four years.
He also holds stock options over 15,000 ordinary shares at an exercise price of 12.584 per share, vesting from March 30, 2022 with 25% after one year and 6.25% per quarter thereafter until fully vested on the four-year anniversary. Additional options cover 60,000 ordinary shares at an exercise price of 2.300 per share, vesting 6.25% per quarter over four years from November 20, 2024.